ATG7 was linked to MSC and osteogenic differentiation in models.
Evidence
The evidence combines single-cell and microarray analyses with OVX mouse validation, MSC assays, and ATG7 overexpression experiments in OVX mouse BMSCs.
Caveat
The therapeutic claim remains preclinical because the validation was in mouse models and cells rather than human osteoporosis outcomes.
Simplified
PURPOSE: is a metabolic bone disorder characterized by reduced bone mass, impaired microarchitecture, and diminished bone strength, resulting in a significantly elevated risk of fractures. It is especially prevalent among older adults, particularly postmenopausal females, and profoundly impacts quality of life. In this study, we integrated osteoporosis-related single-cell RNA sequencing (scRNA-seq) and microarray datasets, to identify the -related gene, which is associated with osteoporosis. ATG7
METHODS: By integrating single-cell transcriptomics with chip data, autophagy-related genes associated with osteoporosis were screened, and cell-cell interactions and developmental trajectories were explored using cell communication and pseudotime analysis. An ovariectomized (OVX) mouse model was established, and verification was performed using micro-CT and immunohistochemistry techniques. Dual-labeled three-color fluorescence technology was employed to further validate the pseudotime analysis results. Additionally, qRT-PCR, Western blot, and other experiments were conducted to assess the expression levels of related genes. Further, ATG7 was overexpressed in OVX mouse BMSCs to investigate its impact on the autophagy process and osteogenic marker proteins.
RESULTS: Pseudotime trajectory analysis revealed a strong link between ATG7 expression and the EYA1 mesenchymal stem cell (MSC) subpopulation. The proportion of EYA1-positive cells and ATG7 expression decreased as osteoporosis progressed.MSCs isolated from OVX mice exhibited diminished expression of autophagy- and osteogenesis-related marker proteins compared to those from normal mice. ATG7 overexpression effectively restored the expression levels of these markers, suggesting its functional role in promoting autophagy and osteogenesis under OP conditions.
CONCLUSION: These findings highlight ATG7 as a critical regulator of MSC differentiation, suggesting that it may serve as a promising therapeutic target for osteoporosis. Modulation of autophagy pathways through ATG7 holds potential for future clinical applications in osteoporosis prevention and treatment.
Key numbers
200 million
Decrease in ATG7 Expression
Estimated number of individuals affected by worldwide.
8.9 million
Fractures Due to
Number of fractures attributed to each year.
Full Text
We can’t show the full text here under this license.
